相关实验视频
Updated: Jul 5, 2025

00:09
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
7.1K
低氧调节A549非小细胞肺癌 (NSCLC) 细胞对不同辐射质量的辐射敏感性和反应
Hasan Nisar1,2, Frederik M Labonté1,3, Marie Denise Roggan1,4
1Department of Radiation Biology, Institute of Aerospace Medicine, German Aerospace Center (DLR), 51147 Cologne, Germany.
International journal of molecular sciences
|January 23, 2024
概括
低氧会在非小细胞肺癌 (NSCLC) 细胞中引起放射电阻,但高LET碳离子显示出比X射线更大的疗效. 这种抗性可能源于细胞周期反应的改变和PI3K介导的细胞机动性的变化,而不是DNA修复.
科学领域:
- 在瘤学瘤学.
- 辐射生物学 辐射生物学
- 分子生物学分子生物学
背景情况:
- 缺氧诱导的放射电阻限制了放射治疗在非小细胞肺癌 (NSCLC) 的有效性.
- 以前的研究无法完全模拟辐射后的体内低氧条件.
- 高线性能量转移 (LET) 碳离子可能克服缺氧诱导的放射电阻,但机制尚不清楚.
研究的目的:
- 研究低氧A549NSCLC细胞对X射线和碳离子的放射电阻.
- 在持续的缺氧下分析细胞周期进展和基因表达.
- 确定碳离子能否克服缺氧诱导的放射电阻.
主要方法:
- A549细胞在正常氧或低氧 (1% O2) 下培养了48小时,然后用X射线或碳离子 (35 MeV/n) 照射.
- 评估了细胞存活率 (殖民地形成能力),DNA双链断裂 (γH2AX),细胞周期进展和基因表达 (RNA测序).
- 在辐射之前,辐射期间和辐射后保持低氧.
主要成果:
- 在晚期涂层测试中观察到过氧诱导的放射电阻;碳离子比X射线更有效.
- 低氧下的细胞存活率对X射线比碳离子更依赖于金时间.
- 低毒细胞表现出较少明显但延长的细胞周期停止;基因表达变化涉及细胞周期调节和PI3K介导的细胞运动.
结论:
- 持续的缺氧在A549 NSCLC细胞中赋予了放射电阻,这在以后的生存测定中尤其明显.
- 高LET碳离子在克服缺氧诱导的放射电阻方面表现出比X射线更高的效率.
- 缺氧诱导的放射电阻与细胞周期反应的改变和PI3K驱动的细胞机动性有关,而不是DNA修复效率.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K

